---

CLINICAL CARDIO-RESPIRATORY DISEASES - BPT 3rd Year

Complete Analysis: Repeated Questions + Frequency + Full Answers

---

PART 1: ALL PAPERS AT A GLANCE

• Section I: 2 x 15 marks = 30
• Section II: 10 x 5 marks = 50
• Section III: 10 x 2 marks = 20

• Section I: 2 x 20 marks = 40
• Section II: 8 x 5 marks = 40
• Section III: 10 x 2 marks = 20

---

PART 2: REPEATED 20-MARK QUESTIONS (Sub Code 6261)

FREQUENCY TABLE - 20 MARK QUESTIONS

---

PART 3: REPEATED 15-MARK QUESTIONS (Sub Code 6286)

FREQUENCY TABLE - 15 MARK QUESTIONS

---

PART 4: MOST REPEATED QUESTIONS (COMBINED BOTH PAPERS)

---

PART 5: DETAILED ANSWERS FOR ALL 20-MARK AND 15-MARK QUESTIONS

---

Q1. CHRONIC BRONCHITIS / COPD

Definition

Etiology

1. Cigarette smoking - most important cause (90% of cases); dose-dependent
2. Air pollution - SO2, NO2, particulate matter
3. Occupational dusts and chemicals - coal dust, silica, grain dust
4. Respiratory infections - viral and bacterial (especially H. influenzae, S. pneumoniae)
5. Genetic factors - alpha-1 antitrypsin deficiency
6. Climate and socioeconomic factors

Pathogenesis

• Cigarette smoke and irritants stimulate hypertrophy and hyperplasia of mucous glands in bronchi
• Reid index (ratio of gland to wall thickness) increases (normal <0.4; in chronic bronchitis >0.5)
• Goblet cell hyperplasia in bronchioles
• Ciliary dysfunction - impaired mucociliary clearance
• Inflammatory infiltration of the bronchial wall
• Excess mucus production leads to airway obstruction
• Hypersecretion, airway narrowing, air trapping - progressive obstruction

Types

1. Simple chronic bronchitis - mucoid sputum, normal spirometry
2. Mucopurulent chronic bronchitis - purulent sputum, recurrent infections
3. Chronic obstructive bronchitis - airflow obstruction (FEV1/FVC < 70%)

Clinical Features

• Productive cough - worse in morning ("morning dip")
• Mucopurulent/purulent sputum
• Dyspnea - initially on exertion, later at rest
• Wheeze and breathlessness
• Cyanosis (blue bloater type)
• Edema due to cor pulmonale

• Barrel chest (increased AP diameter)
• Use of accessory muscles of respiration
• Prolonged expiration
• Coarse crackles and rhonchi on auscultation
• Central cyanosis
• JVP raised in cor pulmonale, ankle edema
• Nicotine staining of fingers

Investigations

1. Spirometry - FEV1 reduced, FVC reduced, FEV1/FVC < 70%, FEV1 % predicted classifies severity (GOLD staging)
   • GOLD I: FEV1 ≥ 80% predicted (mild)
   • GOLD II: 50-79% (moderate)
   • GOLD III: 30-49% (severe)
   • GOLD IV: < 30% (very severe)
2. Chest X-ray - increased bronchovascular markings, cardiomegaly if cor pulmonale
3. ABG - hypoxemia (PaO2 < 60 mmHg), hypercapnia (PaCO2 > 45 mmHg), respiratory acidosis
4. CBC - polycythemia (raised Hb, RBC, PCV), eosinophilia if allergic component
5. Sputum culture - to identify organisms during exacerbations
6. ECG and echo - right ventricular hypertrophy, cor pulmonale

Management

• Smoking cessation - most important; slows disease progression
• Pulmonary rehabilitation
• Nutritional support
• Oxygen therapy - long-term oxygen therapy (LTOT) if PaO2 < 55 mmHg or SpO2 < 88%

• Short-acting bronchodilators: Salbutamol (SABA), Ipratropium (SAMA) - for relief
• Long-acting bronchodilators: Salmeterol, Formoterol (LABA); Tiotropium (LAMA)
• Inhaled corticosteroids (ICS): Budesonide, Fluticasone - added in frequent exacerbations
• Roflumilast - PDE4 inhibitor for severe COPD with frequent exacerbations
• Mucolytics: N-acetylcysteine, carbocisteine

• Oxygen - controlled (24-28% via Venturi mask, target SpO2 88-92%)
• Nebulized bronchodilators (Salbutamol + Ipratropium)
• Systemic corticosteroids - Prednisolone 30-40 mg for 5 days
• Antibiotics (if purulent sputum) - Amoxicillin, Doxycycline, Azithromycin
• Assisted ventilation - NIV (BiPAP) if severe respiratory failure

• Postural drainage and percussion
• Breathing exercises (diaphragmatic, pursed lip breathing)
• Incentive spirometry
• Exercise training
• Airway clearance techniques (ACBT, PEP mask)

Complications

1. Cor pulmonale (right heart failure)
2. Respiratory failure (type II)
3. Pneumothorax
4. Polycythemia
5. Pulmonary hypertension
6. Recurrent infections

---

Q2. MYOCARDIAL INFARCTION (MI)

Definition

Etiology / Risk Factors

• Smoking
• Hypertension
• Hypercholesterolemia (LDL raised)
• Diabetes mellitus
• Obesity
• Physical inactivity
• Stress

• Age (>45 in men, >55 in women)
• Male sex
• Family history of IHD
• Post-menopause in women

• Coronary artery spasm
• Thrombosis on atheromatous plaque
• Coronary artery embolism

Pathogenesis

1. Atherosclerotic plaque formation in coronary artery
2. Plaque rupture/fissure - platelet aggregation begins
3. Thrombus formation - occlusion of coronary artery
4. Cessation of blood flow to myocardium
5. Ischemia → injury → infarction (necrosis) within 20-40 minutes
6. Subendocardial infarction (inner third) progresses to transmural infarction
7. Zones: Central necrosis → zone of injury → zone of ischemia (periphery)

Classification

• STEMI - ST elevation MI; complete occlusion, transmural
• NSTEMI - Non-ST elevation MI; partial occlusion, subendocardial
• Anterior MI - Left anterior descending (LAD) artery
• Inferior MI - Right coronary artery (RCA)
• Lateral MI - Left circumflex artery

Clinical Features

• Severe crushing/squeezing chest pain - central, behind sternum
• Radiation to left arm, jaw, neck, back
• Pain lasting >30 minutes (differentiates from angina)
• Not relieved by rest or nitrates
• Sweating (diaphoresis)
• Nausea, vomiting
• Breathlessness
• Palpitations
• Sense of impending doom (angor animi)
• Silent MI in diabetics and elderly

• Pallor, sweating
• Hypotension or hypertension
• Tachycardia (or bradycardia in inferior MI)
• S3 or S4 gallop sounds
• Pericardial friction rub (if pericarditis)
• Signs of heart failure - raised JVP, basal crepitations

Investigations

1. ECG - cornerstone of diagnosis
   • Hyperacute T waves (early)
   • ST segment elevation (convex upward) in STEMI
   • Q waves (pathological) - >0.04 sec, >25% of R wave height = old MI
   • T wave inversion
   • LBBB (new) = STEMI equivalent
2. Cardiac Biomarkers:
   • Troponin I and T - most specific; rise at 3-6 hrs, peak 24 hrs, remains elevated 7-10 days
   • CKMB - rises at 4-6 hrs, peaks 18-24 hrs, normalizes by 48-72 hrs
   • LDH - rises at 24-48 hrs, peaks 3-5 days
   • Myoglobin - earliest (within 2 hrs) but non-specific
3. Echocardiography - regional wall motion abnormality, EF assessment
4. Coronary angiography - gold standard to identify blocked artery
5. CBC, lipid profile, blood glucose, renal function

Medical Management

• M - Morphine (2.5-5 mg IV) for pain relief
• O - Oxygen (if SpO2 <90%)
• N - Nitrates (sublingual glyceryl trinitrate) - not in hypotension
• A - Aspirin 300 mg stat (antiplatelet)
• • Clopidogrel or Ticagrelor (DAPT)

• Primary PCI (percutaneous coronary intervention) - preferred if available within 90 min (door-to-balloon time)
• Thrombolysis - if PCI not available within 120 min; Streptokinase, tPA, Tenecteplase
  • Contraindications: active bleeding, recent surgery, stroke within 3 months

• Beta blockers (Metoprolol, Carvedilol) - reduce heart rate, infarct size, mortality
• ACE inhibitors (Ramipril, Enalapril) - reduce remodeling, esp. if EF < 40%
• Statins (Atorvastatin 80 mg) - plaque stabilization
• Anticoagulation - Heparin (UFH or LMWH - Enoxaparin)
• Aldosterone antagonist (Spironolactone/Eplerenone) if EF < 40%

Surgical Management

• CABG (Coronary Artery Bypass Grafting) - for multi-vessel disease, left main stenosis, failed PCI
• Internal mammary artery (IMA) or saphenous vein used as graft

Complications

• Cardiogenic shock
• Acute heart failure / pulmonary edema
• Arrhythmias - VF, VT (most common cause of early death), AF
• Cardiac rupture
• Mitral regurgitation (papillary muscle rupture)
• VSD

• Pericarditis (Dressler's syndrome - 2-10 weeks)
• Left ventricular aneurysm
• Thromboembolism
• Chronic heart failure
• Reinfarction

Physiotherapy Management

• Phase I (hospital): early mobilization, breathing exercises, prevent DVT
• Phase II (outpatient): graded exercise, education, risk factor modification
• Phase III (maintenance): regular aerobic exercise, smoking cessation
• Use MET levels to guide activity progression

---

Q3. INFECTIVE ENDOCARDITIS

Definition

Etiology / Risk Factors

• Streptococcus viridans - most common (after dental procedures, native valve)
• Staphylococcus aureus - most common in IV drug users, prosthetic valves, aggressive course
• Streptococcus bovis - associated with colonic carcinoma
• HACEK organisms - Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella
• Fungi (Candida, Aspergillus) - in immunocompromised, IV drug abusers

• Underlying valvular disease (mitral valve prolapse, rheumatic heart disease)
• Congenital heart disease
• Prosthetic heart valves
• IV drug abuse
• Dental/surgical procedures
• Indwelling IV catheters
• Immunocompromised state

Pathogenesis

1. Turbulent blood flow creates endothelial damage
2. Sterile thrombus (fibrin + platelets) forms at the site
3. Transient bacteremia seeds the thrombus
4. Microorganisms colonize and multiply
5. Vegetation forms (fibrin, platelets, bacteria, inflammatory cells)
6. Vegetation may embolize to brain, kidney, spleen, limbs
7. Valve destruction, regurgitation, ring abscess, perforation

Duke Criteria (for Diagnosis)

1. Positive blood cultures (>2 sets with typical organisms)
2. Evidence of endocardial involvement (echocardiography - oscillating mass, abscess, dehiscence; new valvular regurgitation)

1. Predisposing heart condition or IV drug use
2. Fever >38°C
3. Vascular phenomena - arterial emboli, septic pulmonary infarcts, Janeway lesions
4. Immunologic phenomena - Osler nodes, Roth spots, positive RF, glomerulonephritis
5. Positive blood culture not meeting major criteria

Clinical Features

• Fever (most common), night sweats, rigors, malaise, weight loss, anemia

• New/changing heart murmur (regurgitant murmur)
• Heart failure (due to valvular destruction)
• Pericarditis, heart block (if abscess extends)

• Splinter hemorrhages - linear hemorrhages under nails
• Janeway lesions - painless erythematous macules on palms/soles
• Osler nodes - painful tender nodules on finger/toe pads
• Roth spots - retinal hemorrhages with pale center
• Petechiae - conjunctival, mucosal
• Clubbing (subacute IE)
• Splenomegaly

• Stroke (cerebral emboli)
• Renal infarction (hematuria)
• Splenic abscess
• Septic pulmonary emboli (right-sided IE)

Investigations

1. Blood culture - gold standard; 3 sets from different sites before antibiotics
2. Echocardiography - TTE first, then TEE if TTE negative; detects vegetations >2 mm
3. CBC - normocytic normochromic anemia, raised WBC, raised ESR and CRP
4. Urine - hematuria, proteinuria
5. ECG - conduction defects if abscess
6. Rheumatoid factor - may be positive

Management

• Native valve - Streptococcal: Benzyl Penicillin 1.2 g 4-hrly IV + Gentamicin
• Staphylococcal: Flucloxacillin 2 g 6-hrly IV; if MRSA: Vancomycin
• Penicillin allergy: Vancomycin
• Prosthetic valve: Vancomycin + Gentamicin + Rifampicin
• Prophylaxis: Amoxicillin 3 g orally before dental procedures (for high-risk patients)

• Severe heart failure due to valve destruction
• Persistent bacteremia despite antibiotics
• Perivalvular abscess
• Recurrent emboli
• Fungal endocarditis
• Prosthetic valve endocarditis
• Surgery: valve repair or replacement

Physiotherapy Role

• Bed rest during acute phase
• Gradual mobilization as infection resolves
• Breathing exercises to prevent complications
• Post-surgical cardiac rehabilitation

---

Q4. BRONCHIECTASIS

Definition

Etiology

• Childhood infections - measles, whooping cough, adenovirus
• Pulmonary tuberculosis
• Recurrent pneumonias
• Lung abscess

• Cystic fibrosis (most common hereditary cause)
• Primary ciliary dyskinesia (Kartagener syndrome - situs inversus + bronchiectasis + sinusitis)
• Hypogammaglobulinemia (recurrent infections)

• Foreign body aspiration
• Endobronchial tumor
• Extrinsic compression by lymph nodes

• Allergic bronchopulmonary aspergillosis (ABPA) - central bronchiectasis
• Rheumatoid arthritis, inflammatory bowel disease
• Yellow nail syndrome

Pathogenesis

1. Initial insult (infection/obstruction) → inflammation
2. Inflammatory mediators destroy bronchial wall (elastin, smooth muscle, cartilage)
3. Abnormal dilatation persists
4. Impaired mucociliary clearance → pooling of secretions
5. Repeated infections → vicious cycle of inflammation and destruction
6. "Cole's vicious cycle" - infection → inflammation → tissue damage → more infection

Types (Reid classification)

1. Cylindrical/Tubular - uniform dilatation; mild form; reversible
2. Varicose/Fusiform - alternating dilatation and constriction; moderate
3. Saccular/Cystic - balloon-like dilatations; most severe; irreversible

Clinical Features

• Chronic productive cough with copious purulent sputum (3 layers: frothy top, mucoid middle, purulent sediment)
• "Mouthful of sputum" on waking (postural change)
• Hemoptysis - common, occasionally massive (life-threatening)
• Recurrent chest infections and pneumonia
• Breathlessness, pleuritic chest pain
• Systemic features: fever, weight loss, malaise

• Clubbing of fingers (most consistent sign)
• Coarse crepitations and rhonchi over affected areas
• Bronchial breathing if consolidation present
• Signs of respiratory failure in advanced disease

Investigations

1. HRCT Chest - gold standard; shows "signet ring sign" (dilated bronchus > adjacent pulmonary artery), tram-track opacities, cystic changes
2. Chest X-ray - "tram lines" (parallel shadows), ring shadows (cysts en face), honeycomb lung
3. Sputum - culture and sensitivity; H. influenzae, P. aeruginosa, S. aureus
4. Bronchoscopy - localizes bleeding site, excludes obstruction
5. PFT - obstructive pattern (FEV1/FVC reduced)
6. CBC - anemia, raised WBC during infection
7. Sweat chloride test - if cystic fibrosis suspected
8. Ciliary function tests - if ciliary dyskinesia suspected
9. Immunoglobulin levels - if immunodeficiency suspected

Management

• Antibiotics - based on culture; prolonged courses (14-21 days)
  • H. influenzae: Amoxicillin/Co-amoxiclav
  • P. aeruginosa: Ciprofloxacin, Antipseudomonal penicillin
  • Nebulized tobramycin or colistin for chronic P. aeruginosa
• Bronchodilators (salbutamol, ipratropium) if reversible obstruction
• Corticosteroids (if ABPA)
• Mucolytics (DNase in cystic fibrosis)

• Postural drainage - positioning to drain specific bronchopulmonary segments
• Percussion and vibration
• Active cycle of breathing technique (ACBT)
• Positive expiratory pressure (PEP) mask
• Oscillating PEP devices (Flutter, Acapella)
• Exercise training
• Education on self-management

• Lobectomy or segmentectomy for localized disease with frequent exacerbations unresponsive to medical treatment
• Indications: localized disease, recurrent massive hemoptysis, life-threatening bleeding (emergency resection or arterial embolization)
• Lung transplantation for bilateral end-stage disease

Complications

• Massive hemoptysis
• Empyema
• Lung abscess
• Pneumothorax
• Cor pulmonale
• Amyloidosis (secondary, in advanced cases)
• Respiratory failure

---

Q5. ADULT RESPIRATORY DISTRESS SYNDROME (ARDS)

Definition

Etiology

• Pneumonia - most common
• Aspiration of gastric contents
• Pulmonary contusion
• Near-drowning
• Inhalation injury

• Sepsis - most common indirect cause
• Massive blood transfusion
• Severe trauma, burns
• Pancreatitis
• Drug overdose

Pathogenesis

• Alveolar-capillary barrier damage by inflammatory mediators
• Neutrophil activation and infiltration
• Protein-rich fluid floods alveoli (non-cardiogenic pulmonary edema)
• Hyaline membrane formation
• Surfactant dysfunction
• Atelectasis

• Type II pneumocyte proliferation
• Fibroblast proliferation begins

• Progressive fibrosis
• Loss of lung architecture

Clinical Features

• Rapidly progressive dyspnea and tachypnea (within 6-72 hrs of insult)
• Severe hypoxemia despite high FiO2
• Cyanosis
• Bilateral basal crepitations
• Use of accessory muscles
• Confusion (due to hypoxemia)
• Signs of underlying cause (sepsis, trauma, etc.)

Investigations

1. ABG - PaO2/FiO2 ratio:
   • Mild ARDS: 200-300
   • Moderate ARDS: 100-200
   • Severe ARDS: <100
2. Chest X-ray - bilateral diffuse infiltrates/opacities; "white out" appearance
3. CT chest - heterogeneous opacities, dependent consolidation
4. Echocardiography - to exclude cardiogenic pulmonary edema (PCWP < 18 mmHg in ARDS)
5. CBC, cultures, procalcitonin - to identify cause (sepsis)

Management

• Tidal volume: 6 mL/kg of ideal body weight (prevents volutrauma)
• Plateau pressure: < 30 cmH2O (prevents barotrauma)
• PEEP: 5-20 cmH2O to keep alveoli open (prevents atelectrauma)
• FiO2: minimum to maintain SpO2 >88-95%
• Permissive hypercapnia: allow PaCO2 to rise (pH >7.20)
• Prone positioning - improves oxygenation in severe ARDS (>16 hours/day)

• Conservative fluid management (avoid overloading)
• High-flow nasal oxygen (HFNO) / NIV in mild ARDS
• Neuromuscular blockade (Cisatracurium) in severe ARDS - first 48 hrs
• Corticosteroids - may reduce fibrosis in prolonged ARDS (Methylprednisolone)
• Treat underlying cause (antibiotics for sepsis)
• Nutritional support (enteral feeding)

• Prone positioning assistance
• Secretion clearance
• Prevention of ventilator-associated complications
• Early mobilization as tolerated
• Weaning protocols

Complications

• Multi-organ failure (kidney, liver)
• Ventilator-associated pneumonia
• Pneumothorax (due to high pressures)
• Pulmonary fibrosis
• High mortality (30-40% in severe ARDS)

---

Q6. ATRIAL SEPTAL DEFECT (ASD) - OPEN HEART SURGERY

Definition

Types

1. Ostium secundum (70%) - in region of fossa ovalis; most common
2. Ostium primum (20%) - lower septum; associated with AV valve abnormalities
3. Sinus venosus (10%) - near SVC or IVC orifice; associated with PAPVR

Pathophysiology

• Left atrial pressure > Right atrial pressure
• Left-to-right shunt (acyanotic defect)
• Increased blood flow to right heart → right heart volume overload
• Pulmonary plethora (increased blood to lungs)
• Over years: pulmonary hypertension develops
• When pulmonary pressure > systemic: shunt reversal (Eisenmenger syndrome) → right-to-left shunt → cyanosis

Clinical Features

• Often asymptomatic in childhood
• Dyspnea on exertion
• Fatigue
• Recurrent respiratory infections
• Palpitations (atrial arrhythmias - AF common)
• Heart failure (late)

• Fixed split second heart sound (S2) - pathognomonic of ASD
• Pulmonary ejection systolic murmur (flow murmur) - at left upper sternal border
• Mid-diastolic tricuspid flow murmur (if large shunt)
• Parasternal heave (right ventricular hypertrophy)
• Signs of pulmonary hypertension and heart failure (late)
• Cyanosis only if Eisenmenger syndrome

Investigations

1. ECG - Right axis deviation, RBBB (right bundle branch block), rsR' pattern in V1-V3; ostium primum - left axis deviation
2. Chest X-ray - cardiomegaly (right atrial + right ventricular enlargement), prominent pulmonary vasculature, pulmonary plethora
3. Echocardiography - confirms defect location and size; Doppler shows left-to-right shunt; ECHO is gold standard
4. Cardiac catheterization - oxygen step-up in right atrium; pressure measurements

Medical Management

• Small ASDs may close spontaneously in infancy
• Diuretics for heart failure
• Anticoagulation if AF develops
• SBE prophylaxis (now generally not recommended)

Surgical/Interventional Closure

• Pulmonary/systemic flow ratio (Qp:Qs) > 1.5:1
• Right ventricular volume overload
• Age usually 2-5 years
• Before Eisenmenger syndrome develops

1. Device closure (catheter-based) - Amplatzer septal occluder; preferred for secundum ASD < 38 mm
2. Open heart surgical repair:
   • Median sternotomy approach
   • Cardiopulmonary bypass (heart-lung machine)
   • Direct suture closure or pericardial/Dacron patch closure
   • Ostium primum: patch closure + mitral valve repair

• Established Eisenmenger syndrome (pulmonary vascular resistance too high)

Conditions Requiring Open Heart Surgery

1. ASD (ostium primum type, large secundum unsuitable for device)
2. VSD (large, multiple)
3. Tetralogy of Fallot
4. Transposition of great vessels
5. Total anomalous pulmonary venous return
6. Aortic valve surgery (stenosis/regurgitation)
7. Mitral valve surgery
8. CABG (coronary artery bypass)
9. Correction of aortic aneurysm

---

Q7. SUCTION - TYPES, STEPS, INDICATIONS, COMPLICATIONS

Definition

Indications

• Inability to clear secretions by coughing
• Artificial airway (endotracheal tube/tracheostomy) in situ
• Unconscious/semiconscious patient
• Excessive secretions audible or visible
• Respiratory distress due to airway secretions
• SpO2 dropping due to secretion accumulation
• Ventilated patient with rising airway pressures

Types of Suction

• For secretions in upper airway
• Catheter inserted via nose or mouth
• Suitable for patients who can partially clear secretions

• Blind insertion of catheter through nose into trachea
• For patients without artificial airway
• Requires skill and is more uncomfortable

• Through endotracheal tube or tracheostomy
• Deeper airway clearance
• Most effective in ventilated patients

Equipment

• Suction catheter (size: external diameter = (ETT size - 2) x 2, or use Fr size: Fr = (ETT internal diameter - 2) x 3)
• Suction unit (wall-mounted or portable)
• Suction pressure: 80-120 mmHg (adults), 60-80 mmHg (children)
• Sterile gloves, water for irrigation, bag-valve mask

Steps (Technique for Endotracheal Suction)

1. Explain procedure to patient (if conscious)
2. Wash hands, assemble equipment, don sterile gloves
3. Pre-oxygenate - 100% O2 for 30 seconds before suction (prevents hypoxia)
4. Set suction pressure to 80-120 mmHg
5. Insert catheter gently into the ETT/tracheostomy without applying suction; advance until resistance felt (carina level)
6. Withdraw 1 cm, then apply suction while withdrawing in a rotating motion
7. Duration: no more than 10-15 seconds per pass
8. Re-oxygenate between passes (100% O2)
9. Allow recovery - minimum 30 seconds between passes
10. Maximum 3 passes per suction episode
11. Flush catheter with sterile water
12. Auscultate chest after procedure to assess clearance
13. Document - color, amount, consistency of secretions; patient response

Complications

• Hypoxemia - most common; prevented by pre-oxygenation
• Hypercapnia - due to interruption of ventilation
• Arrhythmias - bradycardia (vagal), tachycardia
• Hypo/Hypertension
• Increased intracranial pressure (ICP) - avoid in head injury patients
• Bronchoconstriction

• Mucosal trauma - hemorrhage, ulceration
• Atelectasis (if too large catheter)
• Pneumothorax (rare)

• VAP (Ventilator-associated pneumonia) - use aseptic technique
• Cross-infection - use single-use catheters

• Coughing, gagging, anxiety
• Cardiac arrest (rare - profound hypoxia or vagal response)

---

Q8. BRONCHIAL ASTHMA

Definition

Etiology / Triggers

• Genetic predisposition (family history)
• Atopy (raised IgE)

• Allergens: house dust mite (Dermatophagoides), animal dander, pollen, mold, cockroach
• Exercise (exercise-induced asthma)
• Cold air, change in weather
• Respiratory infections (viral URTI)
• NSAIDs / Aspirin (Samter's triad - asthma + nasal polyps + aspirin sensitivity)
• Beta-blockers (contraindicated)
• Occupational agents (isocyanates, latex)
• Emotional stress
• Air pollution

Types

1. Extrinsic (allergic) asthma - atopic; IgE-mediated; starts in childhood
2. Intrinsic (non-atopic) asthma - adult onset; no identifiable allergen; often triggered by infections
3. Exercise-induced asthma
4. Occupational asthma
5. Aspirin-sensitive asthma
6. Nocturnal asthma

Pathophysiology

1. Exposure to allergen/trigger
2. IgE-mediated mast cell degranulation (early phase - 15-30 min)
3. Release of histamine, leukotrienes, prostaglandins → bronchoconstriction
4. Late phase (4-6 hours) - eosinophil infiltration, cytokine release
5. Airway inflammation → edema, mucus hypersecretion
6. Smooth muscle hypertrophy and hyperresponsiveness
7. Airway remodeling in chronic asthma

Clinical Features

• Recurrent episodic wheezing (bilateral, expiratory)
• Chest tightness
• Breathlessness (dyspnea)
• Cough - especially nocturnal
• Worse with triggers, at night, or early morning

• Tachycardia, tachypnea
• Use of accessory muscles
• Hyperinflated chest
• Diffuse bilateral wheeze (expiratory > inspiratory)
• Prolonged expiratory phase
• Pulsus paradoxus (>10 mmHg) in severe attack

• Unable to complete sentence
• Respiratory rate >25/min
• Heart rate >110/min
• PEFR < 50% predicted
• SpO2 < 92%

• Silent chest (no wheeze - indicates very severe obstruction)
• Cyanosis
• Bradycardia, hypotension
• Confusion

Investigations

1. Peak Expiratory Flow Rate (PEFR) - reduced during attack; diurnal variation >20% diagnostic
2. Spirometry - FEV1 reduced, FVC reduced/normal, FEV1/FVC reduced; reversibility with bronchodilator (>12% and >200 mL increase in FEV1)
3. Bronchial provocation test (methacholine challenge) - for diagnosis when spirometry normal
4. Allergy tests - skin prick test, RAST (specific IgE)
5. Total and specific IgE - raised in atopic asthma
6. CBC - eosinophilia
7. Chest X-ray - hyperinflation; exclude pneumothorax in severe attack
8. ABG - in severe/life-threatening attack (normal or low PaCO2 in early attack; rising PaCO2 = fatigue = ICU)

Management

• Step 1: As-needed low-dose ICS + formoterol or SABA alone
• Step 2: Low-dose ICS daily + SABA as needed
• Step 3: Low-dose ICS + LABA (e.g., Budesonide/Formoterol)
• Step 4: Medium/high-dose ICS + LABA
• Step 5: Add-on therapy - Tiotropium, anti-IgE (Omalizumab), anti-IL5 (Mepolizumab)

• Oxygen - high flow to maintain SpO2 94-98%
• Nebulized Salbutamol (2.5-5 mg) every 20 minutes x 3 doses, then hourly
• Nebulized Ipratropium bromide (0.5 mg)
• Systemic corticosteroids (Prednisolone 40-60 mg oral or Hydrocortisone 100 mg IV)
• IV Magnesium sulfate (1.2-2 g over 20 min) in severe attack
• IV Aminophylline (if no improvement)
• Intubation and mechanical ventilation if life-threatening

• Severe attack lasting >24 hours or not responding to treatment
• ICU care, IV bronchodilators, corticosteroids, intubation if needed

• Breathing exercises (diaphragmatic breathing, pursed lip breathing)
• Relaxation techniques
• Position of comfort (sitting forward, arms supported)
• Education on inhaler technique, trigger avoidance, self-monitoring with peak flow
• Breathing retraining (Buteyko technique)

---

Q9. ANGINA PECTORIS

Definition

Types

1. Stable angina - predictable, on exertion, relieved by rest within 5 min or nitrates
2. Unstable angina - increasing frequency/severity, occurs at rest, new onset, part of ACS
3. Variant (Prinzmetal's) angina - due to coronary artery spasm; occurs at rest, often nocturnal; ST elevation
4. Microvascular angina (Cardiac Syndrome X) - normal coronary arteries; due to small vessel disease

Etiology / Risk Factors

Pathophysiology

• Atherosclerotic narrowing of coronary arteries (>70% stenosis = significant)
• Supply-demand mismatch of myocardial oxygen
• During exertion: increased demand, fixed supply → ischemia
• Anaerobic metabolism → lactic acid → pain

Clinical Features

• Central/retrosternal chest pain, "pressing/squeezing/tight" character
• Radiation to left arm, jaw, shoulder, back
• Triggered by exertion, cold, emotion, meals
• Duration: 2-10 minutes
• Relieved by rest (within 5 min) or GTN (within 2 min)
• Associated: breathlessness, nausea, diaphoresis
• Canadian Cardiovascular Society (CCS) Classification:
  • Class I: No angina with ordinary activity
  • Class II: Slight limitation - angina on rapid walking/stairs
  • Class III: Marked limitation - angina on walking 1-2 level blocks
  • Class IV: Inability to carry on any activity without angina

Investigations

1. Resting ECG - may be normal; ST depression, T wave changes during attack
2. Exercise ECG (Treadmill test/Stress test) - horizontal ST depression >1 mm is positive
3. Echocardiography - regional wall motion abnormalities during stress
4. Nuclear imaging (MIBI, thallium scan) - perfusion defects
5. Coronary angiography - gold standard; identifies stenosis location and degree
6. Lipid profile, blood glucose, renal function

Medical Management

• GTN (glyceryl trinitrate) sublingual tablet or spray - 0.3-0.5 mg; repeat in 5 min if no relief

• Beta blockers (Atenolol, Metoprolol) - first line; reduce HR and myocardial O2 demand
• Nitrates (Isosorbide mononitrate) - long-acting; venodilators, reduce preload
• Calcium channel blockers (Amlodipine, Diltiazem, Verapamil) - reduce heart rate, vasodilate
• Ivabradine - If-channel blocker; reduces heart rate if beta-blocker contraindicated
• Ranolazine - late sodium current inhibitor; useful in refractory angina

• Aspirin 75 mg daily (or Clopidogrel)
• Statin (Atorvastatin 40-80 mg)
• ACE inhibitor (if hypertension/DM/LV dysfunction)

Interventional/Surgical Management

1. Percutaneous Coronary Intervention (PCI) - angioplasty + stent (drug-eluting stent preferred)
   • For single or double vessel disease, accessible lesions
2. CABG (Coronary Artery Bypass Grafting) - for triple vessel disease, left main disease, failed PCI, diabetics with multi-vessel disease

Physiotherapy

• Graded exercise program (cardiac rehabilitation)
• Monitor HR, BP, ECG during exercise
• Target HR = 70-85% of age-predicted maximum
• Stop exercise if symptoms appear
• Phase I, II, III cardiac rehabilitation

---

Q10. AORTIC STENOSIS

Definition

Etiology

1. Calcific (degenerative) AS - most common; elderly (>65 years); calcium deposition on normal tricuspid valve
2. Bicuspid aortic valve - most common cause in young adults (<65 years); congenital bicuspid valve calcifies earlier
3. Rheumatic AS - following rheumatic fever; commissural fusion; valve leaflets fuse; usually combined with mitral disease
4. Congenital AS - isolated subvalvular, valvular, or supravalvular

Pathophysiology

• Narrowed aortic valve → obstruction to LV outflow
• LV pressure rises to maintain cardiac output
• LV concentric hypertrophy (compensatory)
• Increased myocardial O2 demand with impaired coronary filling
• Eventually: LV failure, reduced cardiac output, pulmonary edema
• Normal valve area: 3-4 cm²; Severe AS: <1 cm²

Clinical Features (Classic Triad - SAD):

• Slow-rising, plateau pulse (pulsus parvus et tardus)
• Narrow pulse pressure
• Heaving apex beat (forceful, non-displaced if LV compensated)
• Systolic thrill at right upper sternal border
• Ejection systolic murmur (crescendo-decrescendo) at aortic area (2nd right intercostal space) - radiates to carotids
• Soft A2 or absent A2 (as valve calcifies)
• Reverse split of S2 (in severe AS - LBBB pattern)

Investigations

1. ECG - LV hypertrophy (Sokolow-Lyon criteria: S in V1 + R in V5 >35 mm), LBBB, AF
2. Chest X-ray - LV enlargement (late), post-stenotic aortic dilatation, calcification of aortic valve
3. Echocardiography - gold standard; valve area, peak gradient (severe = mean gradient >40 mmHg or valve area <1 cm²), LV function
4. Cardiac catheterization - if echo inconclusive; direct measurement of pressure gradient

Management

• No effective medical therapy to slow progression
• Treat co-existing conditions (hypertension, heart failure)
• Diuretics for pulmonary edema (with caution - avoid hypotension)
• Avoid vasodilators (nitrates, ACE inhibitors can cause profound hypotension in severe AS)
• SBE prophylaxis (debated in current guidelines)
• Statins - do NOT slow progression (SEAS trial)

• Surgical Aortic Valve Replacement (SAVR) - gold standard for suitable surgical candidates
  • Mechanical valve (requires lifelong anticoagulation) or Bioprosthetic valve (no anticoagulation but shorter durability)
  • Performed via median sternotomy + cardiopulmonary bypass
• TAVI/TAVR (Transcatheter Aortic Valve Implantation/Replacement) - for high surgical risk patients; catheter-based valve delivery (usually transfemoral or transapical)
• Balloon valvuloplasty - temporary palliation (bridge to surgery); high restenosis rate

• Symptomatic severe AS (SAD symptoms)
• Severe AS with EF < 50%
• Undergoing other cardiac surgery with severe AS

---

Q11. PLEURAL EFFUSION

Definition

Etiology

• Heart failure (most common cause of transudate)
• Nephrotic syndrome
• Liver cirrhosis
• Hypoalbuminemia
• Hypothyroidism
• Meigs syndrome (ovarian fibroma)

• Pneumonia (parapneumonic effusion)
• Malignancy (carcinoma lung, mesothelioma, breast cancer metastasis) - most common cause of bilateral exudate
• Tuberculosis (most common cause of lymphocytic exudate in developing countries)
• Pulmonary embolism
• Autoimmune disease (SLE, RA)
• Pancreatitis (left-sided)
• Post-cardiac injury (Dressler's syndrome)

• Hemothorax (blood)
• Empyema (pus)
• Chylothorax (chyle - lymphatic obstruction)

Clinical Features

• Breathlessness (proportional to size)
• Pleuritic chest pain (if associated pleuritis)
• Dry cough
• Fever, weight loss, night sweats (if TB/malignancy)
• Symptoms of underlying cause

• Tracheal deviation AWAY from effusion (if large)
• Decreased chest expansion on affected side
• Stony dull percussion note (most characteristic)
• Diminished or absent breath sounds
• Vocal resonance decreased (aegophony at upper border)
• Bronchial breathing at the upper margin (compressed lung - due to area of consolidation)

Investigations

1. Chest X-ray - blunting of costophrenic angle (>200 mL needed), meniscus sign, mediastinal shift
2. USG chest - detects as little as 50 mL; guided aspiration
3. CT chest - characterizes effusion, identifies cause (malignancy, empyema)
4. Diagnostic Thoracocentesis / Pleural tap:
   • Aspiration of fluid
   • Biochemistry: protein, LDH, glucose, pH (Light's criteria)
   • Cytology - malignant cells
   • Culture and sensitivity (bacteria, TB - ZN stain, AFB culture)
   • ADA (adenosine deaminase) - raised in TB effusion (>40 U/L)
5. Pleural biopsy (Abrams needle or VATS) - if cytology negative and malignancy/TB suspected

Management

• Drain no more than 1-1.5 L at a time (risk of re-expansion pulmonary edema)
• For symptomatic relief of dyspnea

• For large symptomatic effusion
• For empyema (pus must be drained)
• For hemothorax

• For recurrent malignant effusion
• Talc or doxycycline instilled through drain
• Creates adhesion between pleural layers

• TB effusion: Anti-tubercular treatment (HRZE)
• Malignant: Treat underlying cancer; pleurodesis or indwelling pleural catheter
• Heart failure: Diuretics

Physiotherapy

• Breathing exercises to re-expand lung after drainage
• Incentive spirometry
• Postural drainage (not for effusion per se, but post-drainage)
• Progressive mobilization

---

Q12. TETRALOGY OF FALLOT (TOF)

Definition

Four Components (PROVE)

1. P - Pulmonary stenosis (right ventricular outflow obstruction) - most important determinant of symptoms
2. R - Right ventricular hypertrophy - due to obstruction
3. O - Overriding aorta - aorta straddles the VSD (receives blood from both ventricles)
4. VSD (Ventricular septal defect) - large, non-restrictive perimembranous VSD

Pathophysiology

• Pulmonary stenosis → increased RV pressure → right-to-left shunt through VSD
• Deoxygenated blood from RV enters aorta directly
• Degree of cyanosis depends on severity of pulmonary stenosis
• Mild PS: "Pink Tet" - minimal cyanosis
• Severe PS: profound cyanosis

Clinical Features

• Cyanosis - present from birth or early infancy (worsens with crying/feeding)
• Dyspnea on exertion
• Squatting posture - child squats after exercise; increases systemic vascular resistance → reduces right-to-left shunt → temporary improvement (pathognomonic)
• Hypoxic/cyanotic spells ("Tet spells") - sudden episodes of severe cyanosis, breathlessness, syncope; more in morning; triggered by crying, feeding, exercise
• Growth retardation, delayed milestones

• Central cyanosis - tongue, lips, mucous membranes
• Clubbing of fingers and toes (after 6 months)
• Single S2 (A2 loud, P2 absent or soft - due to reduced pulmonary flow)
• Ejection systolic murmur at left upper sternal border (due to pulmonary stenosis - NOT due to VSD; VSD is large and pressure equal so no murmur)
• Right ventricular heave
• Right-sided aortic arch (25% cases)

Investigations

1. ECG - right axis deviation, right ventricular hypertrophy (tall R in V1, deep S in V5/V6)
2. Chest X-ray - "Boot-shaped heart" (coeur en sabot) - elevated cardiac apex + absent pulmonary bay; pulmonary oligemia (reduced vascular markings)
3. Echocardiography - confirms all four components; definitive diagnosis
4. Cardiac catheterization and angiography - pre-surgical planning; shows anatomy

Management

• Treat hypoxic spells:
  • Knee-chest position (or squatting)
  • 100% oxygen
  • IV Morphine (reduces hyperpnea and anxiety)
  • IV Propranolol (relaxes RV infundibulum)
  • IV fluid bolus
  • Sodium bicarbonate (for metabolic acidosis)
  • Phenylephrine (increase SVR)
• Long-term beta-blocker (Propranolol) to reduce spell frequency
• Iron supplementation (if iron deficiency anemia)
• SBE prophylaxis
• Prostaglandin E1 (if duct-dependent - neonates with severe PS)

1. Palliative shunt (temporizing):
   • Modified Blalock-Taussig (mBT) shunt - subclavian artery to pulmonary artery anastomosis
   • Done in neonates/infants before definitive repair
2. Complete intracardiac repair (definitive):
   • VSD patch closure
   • Relief of pulmonary stenosis (pulmonary valvotomy + infundibular resection)
   • Done at 3-6 months to 2 years age
   • Performed via median sternotomy + cardiopulmonary bypass

Complications

• Polycythemia (due to chronic hypoxia)
• Brain abscess, stroke
• Infective endocarditis
• Pulmonary regurgitation (post-repair)
• Right ventricular dysfunction
• Residual VSD

---

Q13. RHEUMATIC FEVER

Definition

Etiology

• Group A beta-hemolytic Streptococcus (GABHS) pharyngeal infection
• Molecular mimicry: antibodies against streptococcal M protein cross-react with cardiac tissues
• Predominantly affects children (5-15 years)
• Uncommon in developed countries but prevalent in developing countries

Pathogenesis

1. GABHS throat infection
2. Antibodies formed against M protein (on bacterial surface)
3. Cross-reactivity with cardiac proteins (myosin, tropomyosin, laminin, vimentin)
4. Cardiac inflammation: pancarditis (endocarditis + myocarditis + pericarditis)
5. Aschoff bodies (pathognomonic) - granulomatous lesions in myocardium
6. Mitral valve most commonly affected → mitral stenosis (long-term)

Jones Criteria (for Diagnosis of RF)

1. J - Joints (Migratory polyarthritis) - affects large joints (knee, ankle, wrist, elbow); one joint improves as another is affected; most common feature
2. O - (c)Oarditis (Carditis) - pancarditis; most serious; mitral regurgitation murmur; pericardial rub; cardiomegaly on CXR; detected in 40-50%
3. N - Nodules (subcutaneous nodules) - painless, over bony prominences (elbows, wrists); rare
4. E - Erythema marginatum - pink rings on skin of trunk; transient; rare
5. S - Sydenham's chorea (St. Vitus dance) - involuntary, irregular movements; occurs late (3 months); only after RF (pathognomonic)

1. Fever (>38.5°C)
2. Elevated acute phase reactants (raised ESR, CRP)
3. Prolonged PR interval on ECG
4. Arthralgia (only if arthritis not used as major)

Clinical Features

• Fever, malaise, anorexia
• Migratory polyarthritis (most common - 75%)
• Carditis - chest pain, pericardial rub, murmurs, breathlessness
• Erythema marginatum - skin rash
• Subcutaneous nodules
• Sydenham's chorea (late)

Investigations

1. ASO titer (anti-streptolysin O) - raised (>200 Todd units); peaks at 3-5 weeks
2. Throat culture - GABHS (may be negative if treated)
3. ESR, CRP - raised
4. ECG - prolonged PR interval, ST changes
5. Echocardiography - mitral/aortic regurgitation, pericardial effusion
6. CBC - leukocytosis, anemia

Management

• Benzyl Penicillin 1.2 MU IM (single dose)
• OR Phenoxymethylpenicillin 500 mg orally x 10 days
• If allergic to penicillin: Erythromycin

• Arthritis: Aspirin 80-100 mg/kg/day (in children) until ESR normalizes
• Carditis: Prednisolone 2 mg/kg/day x 2 weeks, then taper; (corticosteroids for moderate-severe carditis)
• Bed rest during acute phase

• Benzathine Penicillin 1.2 MU IM every 3-4 weeks
• Duration:
  • No carditis: 5 years or till 21 years (whichever longer)
  • Carditis without residual valve disease: 10 years or till 21 years
  • Carditis with residual valve disease: until 40 years or lifelong

• Heart failure: Diuretics, ACE inhibitors, digoxin
• Mitral stenosis: Balloon mitral valvotomy or surgical commissurotomy

---

Q14. HYPERTENSION

Definition

• JNC 8 / AHA 2017: ≥130/80 mmHg
• WHO/ISH 2020: ≥140/90 mmHg

Classification (JNC 8)

• Normal: <120/80
• Elevated: 120-129/<80
• Stage 1 HTN: 130-139/80-89
• Stage 2 HTN: ≥140/≥90
• Hypertensive crisis: >180/120 (emergency if organ damage; urgency if not)

Etiology

• No identifiable cause
• Multifactorial: genetic + environmental factors
• Risk factors: obesity, salt intake, physical inactivity, alcohol, smoking, stress, family history

• Renal: Chronic kidney disease (most common secondary cause), renal artery stenosis (renovascular HTN)
• Endocrine: Primary hyperaldosteronism (Conn's syndrome), Pheochromocytoma, Cushing's syndrome, Hyperthyroidism, Acromegaly
• Vascular: Coarctation of aorta
• Drugs: OCP, NSAIDs, corticosteroids, sympathomimetics, cocaine
• Pregnancy: Gestational HTN, Pre-eclampsia, Eclampsia

Pathophysiology

• Increased cardiac output or increased peripheral vascular resistance
• Renin-angiotensin-aldosterone system (RAAS) activation
• Sympathetic nervous system overactivity
• Sodium and water retention
• Vascular smooth muscle hypertrophy → increased resistance

Clinical Features

• Headache (occipital, morning)
• Dizziness, tinnitus
• Epistaxis
• Visual disturbance (hypertensive retinopathy)

• Severe headache, visual changes, chest pain, dyspnea, confusion

• Raised BP on measurement
• Left ventricular heave (LVH)
• Fundoscopy: AV nipping, flame hemorrhages, papilledema (grade IV)
• Narrow pulsation, forceful brachial pulse

Target Organ Damage

• Heart: LV hypertrophy, coronary artery disease, heart failure
• Brain: Stroke, TIA, hypertensive encephalopathy
• Kidneys: Nephrosclerosis, renal failure, proteinuria
• Eyes: Retinopathy (Keith-Wagener-Barker grades I-IV), retinal artery occlusion
• Aorta/Arteries: Aortic dissection, peripheral arterial disease

Investigations

1. BP measurement - repeated readings
2. Urinalysis - protein, blood (renal involvement)
3. Serum creatinine, eGFR - renal function
4. Lipid profile, blood glucose - cardiovascular risk
5. ECG - LV hypertrophy
6. Echocardiography - LV mass, diastolic dysfunction
7. Fundoscopy - retinopathy grading
8. Chest X-ray - cardiomegaly
9. Secondary cause workup - renal ultrasound, plasma renin/aldosterone, cortisol, urine catecholamines (if suspected)

Management

• Salt restriction (<6 g/day)
• Weight reduction (target BMI 18.5-24.9)
• Regular aerobic exercise (30 min, 5 days/week)
• Smoking cessation
• Alcohol moderation (<2 units/day for men, <1 for women)
• DASH diet (rich in fruits, vegetables, low-fat dairy; low sodium, saturated fat)
• Stress management

• 1st line drugs (NICE/JNC):
  • ACE inhibitors (Ramipril, Lisinopril) - preferred in DM, CKD, heart failure
  • ARBs (Losartan, Telmisartan) - if ACE inhibitor cough
  • Calcium channel blockers (Amlodipine, Felodipine) - preferred in elderly, Afro-Caribbean
  • Thiazide diuretics (Indapamide, Chlortalidone)
  • Beta blockers (Atenolol, Bisoprolol) - not first-line; use in angina, MI, heart failure

• Step 1: ACE inhibitor or CCB
• Step 2: ACE inhibitor + CCB
• Step 3: ACE inhibitor + CCB + Thiazide
• Step 4 (resistant HTN): Add Spironolactone (25-50 mg) or other agents

• Admit to ICU
• Labetalol IV, Sodium nitroprusside IV, Hydralazine IV
• Target: reduce BP by 25% in first hour, then gradually to 160/100 over next 24 hours

---

Q15. CARCINOMA LUNG

Definition

Etiology / Risk Factors

1. Cigarette smoking - causative in 85-90%; risk proportional to pack-year history
2. Passive smoking (second-hand smoke)
3. Radon gas (second most common cause)
4. Occupational carcinogens: asbestos (synergy with smoking), arsenic, chromate, nickel, coal tar
5. Air pollution
6. Previous lung diseases: COPD, TB, IPF (adenocarcinoma risk)
7. Genetic factors: family history

Types / Histological Classification

1. Adenocarcinoma (40%) - most common; peripheral location; arises from type II pneumocytes; associated with non-smokers; EGF receptor mutations (EGFR); BAC subtype
2. Squamous cell carcinoma (30%) - central location; arises from bronchial epithelium; slow growing; cavitation common; hypercalcemia (PTHrP production); Pancoast tumor
3. Large cell carcinoma (10%) - peripheral; undifferentiated; poor prognosis

• Central; from neuroendocrine cells (Kulchitsky cells)
• Rapid growth; early metastasis
• ACTH, ADH, serotonin production (paraneoplastic)
• Highly chemosensitive (responds well to chemo)

Clinical Features

• Cough (persistent, new change in character)
• Hemoptysis
• Dyspnea, wheeze, stridor
• Chest pain (pleuritic or dull)
• Recurrent pneumonia (due to obstruction)

• SVC obstruction syndrome: swelling of face/neck/arms, headache worse on bending
• Phrenic nerve palsy: raised hemidiaphragm
• Recurrent laryngeal nerve palsy: hoarse voice
• Dysphagia (esophageal compression)
• Cardiac tamponade

• Shoulder/arm pain (brachial plexus - C8, T1, T2)
• Wasting of hand muscles
• Horner syndrome (cervical sympathetic chain involvement): ptosis, miosis, anhidrosis, enophthalmos

• Brain: headache, seizures, focal deficits
• Bone: pain, pathological fracture (spine, ribs)
• Liver: jaundice, hepatomegaly
• Adrenal: Addison's disease

• SCLC: SIADH (hyponatremia), ectopic ACTH (Cushing's), Lambert-Eaton myasthenic syndrome, peripheral neuropathy
• Squamous cell: Hypercalcemia (PTHrP)
• All types: Clubbing, hypertrophic pulmonary osteoarthropathy (HPOA), dermatomyositis

Investigations

1. Chest X-ray - central mass, hilar enlargement, collapse/consolidation, pleural effusion, raised hemidiaphragm
2. CT chest and upper abdomen - staging (extent of tumor and mediastinal lymph nodes)
3. PET-CT - gold standard for staging; identifies distant metastases
4. Bronchoscopy + biopsy - for central tumors; bronchial lavage, brush biopsy
5. CT-guided fine needle aspiration - for peripheral tumors
6. Sputum cytology - low sensitivity
7. Mediastinoscopy - biopsy of mediastinal nodes
8. Bone scan, brain MRI - for metastases
9. Lung function tests - pre-surgical assessment

• Stage I/II: localized, surgical resection possible
• Stage III: locally advanced
• Stage IV: metastatic

Management

• Stage I/II: Surgical resection (lobectomy preferred; pneumonectomy if necessary); adjuvant chemotherapy
• Stage III: Chemoradiation (concurrent carboplatin/paclitaxel + radiotherapy)
• Stage IV: Palliative chemotherapy (platinum-based doublet: Cisplatin + Docetaxel/Gemcitabine); targeted therapy if EGFR/ALK mutations (Gefitinib, Erlotinib, Crizotinib); immunotherapy (Pembrolizumab for PD-L1 +)

• Limited disease: Chemoradiation (Cisplatin + Etoposide + RT); prophylactic cranial irradiation
• Extensive disease: Chemotherapy (Cisplatin + Etoposide); palliative RT

• Pre-operative assessment and optimization
• Post-surgical breathing exercises, early mobilization
• Sputum clearance techniques
• Pulmonary rehabilitation
• Palliative - symptom management, dyspnea relief

Prognosis

• 5-year survival: Stage I ~70%, Stage IV <5%
• SCLC: very poor (median survival untreated: 3 months)

---

Q16. PNEUMOTHORAX

Definition

Types

1. Spontaneous pneumothorax:
   • Primary (PSP): in young, tall, thin men; subpleural bleb rupture; no underlying lung disease
   • Secondary (SSP): underlying lung disease (COPD, asthma, TB, cystic fibrosis, pneumonia)
2. Traumatic: Penetrating chest trauma, rib fracture, iatrogenic (central line insertion, pleural aspiration, mechanical ventilation)
3. Tension pneumothorax: Air enters pleural space but cannot escape (valve mechanism); increasing air causes mediastinal shift; life-threatening emergency

Clinical Features

• Sudden onset unilateral chest pain (pleuritic)
• Breathlessness
• Tachycardia
• Decreased chest expansion on affected side
• Hyperresonant percussion
• Diminished/absent breath sounds

• Above + hemodynamic compromise
• Tracheal deviation AWAY from affected side
• Raised JVP
• Hypotension, shock
• Cyanosis
• Absent breath sounds

Investigations

• Chest X-ray - definitive; absence of lung markings beyond the visceral pleura line; estimated size
• CT chest - if diagnosis uncertain; identifies blebs

Management

• 4th/5th intercostal space, anterior axillary line
• Connected to underwater seal drain
• Removed when lung re-expanded and <100 mL air leaking

• VATS (Video-assisted thoracoscopic surgery) + bullectomy + pleurodesis
• Open thoracotomy if VATS unavailable
• Chemical pleurodesis (talc) to prevent recurrence

---

Q17. HEART FAILURE

Definition

Classification

• Systolic (HFrEF): EF < 40%; impaired contractility (MI, cardiomyopathy)
• Diastolic (HFpEF): EF > 50%; impaired relaxation/filling (hypertension, hypertrophic CM)
• Right heart failure / Left heart failure / Biventricular (congestive) failure
• Acute vs Chronic heart failure

Etiology

• IHD/MI (most common)
• Hypertension
• Cardiomyopathy
• Aortic/mitral valve disease
• Arrhythmias

• Left heart failure (most common cause of RHF)
• Cor pulmonale (chronic lung disease)
• Pulmonary hypertension
• Right ventricular MI

Pathophysiology

1. Reduced cardiac output
2. Compensatory mechanisms: SNS activation (tachycardia, vasoconstriction), RAAS activation (Na/water retention), cardiac hypertrophy and remodeling
3. These initially maintain CO but ultimately worsen cardiac function
4. Frank-Starling mechanism (ventricular dilation) - initially helps, then fails
5. Progressive deterioration: pulmonary edema (left), peripheral edema (right)

Clinical Features

• Dyspnea on exertion (earliest)
• Orthopnea (need extra pillows)
• PND (paroxysmal nocturnal dyspnea)
• Cough (frothy pink sputum in acute pulmonary edema)
• Fatigue, exercise intolerance
• NYHA Classification (I to IV)

• Tachycardia
• S3 gallop (most specific sign of LVF)
• Raised JVP
• Basal crepitations (pulmonary edema)
• Pleural effusion (bilateral)
• Displaced apex beat (cardiomegaly)
• Cheyne-Stokes breathing (severe)

• Ankle/leg edema
• Ascites
• Hepatomegaly (tender)
• JVP raised
• RV heave

Investigations

1. BNP/NT-proBNP - elevated; best biomarker; raised BNP >100 pg/mL suggests HF
2. ECG - LVH, AF, ischemic changes, LBBB
3. Echocardiography - gold standard; EF assessment, wall motion, valves
4. Chest X-ray (ABCDE of pulmonary edema): Alveolar edema, Kerley B lines, Cardiomegaly, Dilated upper lobe veins, Effusion (pleural)
5. Renal function, electrolytes, LFT - before starting treatment
6. CBC - anemia worsens HF

Management

• Salt restriction (<2 g/day), fluid restriction
• Daily weight monitoring
• Vaccinations (influenza, pneumococcal)
• Smoking cessation
• Exercise rehabilitation

• Diuretics - Furosemide (first-line for congestion/edema); relieves symptoms
• ACE inhibitors/ARBs - reduce mortality; Ramipril, Enalapril
• Beta blockers - reduce mortality (Carvedilol, Bisoprolol, Metoprolol) - start low, go slow
• Aldosterone antagonists - Spironolactone, Eplerenone - in EF <35%
• ARNI (Sacubitril/Valsartan - Entresto) - superior to ACE inhibitor; reduces mortality
• SGLT2 inhibitors (Dapagliflozin, Empagliflozin) - reduce hospitalizations and mortality
• Digoxin - for rate control in AF + HF; modest benefit in sinus rhythm
• Hydralazine + Nitrates - if ACE inhibitor intolerant

• ICD (implantable cardioverter defibrillator) - if EF < 35%, LBBB
• CRT (Cardiac resynchronisation therapy/biventricular pacing) - if EF <35% + QRS > 130 ms (LBBB)
• LVAD (Left ventricular assist device) - bridge to transplant

• Sit upright
• Oxygen/NIV (CPAP)
• IV Furosemide
• IV nitrates (if not hypotensive)
• Morphine (cautious)

---

Q18. MITRAL STENOSIS

Definition

Etiology

• Rheumatic fever - most common cause (>90%); valve leaflet fusion at commissures
• Congenital MS (rare)
• Calcific MS in elderly
• SLE, carcinoid syndrome (rare)

Pathophysiology

• Narrowed valve → obstruction to LA-LV flow
• LA pressure rises → pulmonary venous hypertension → pulmonary edema
• LA enlarges → AF common
• Pulmonary arterial hypertension develops over time
• Right heart failure eventually

Clinical Features

• Dyspnea on exertion (earliest)
• Orthopnea, PND
• Hemoptysis (Pulmonary apoplexy)
• Palpitations (AF is common)
• Systemic emboli (AF + LA clot → stroke)
• Hoarse voice (Ortner syndrome - LA compresses left recurrent laryngeal nerve)
• Symptoms of right heart failure (late)

• Malar flush (butterfly distribution - mitral facies)
• Tapping apex beat (palpable S1)
• Loud S1 (as valve snaps shut from open position)
• Opening snap - early diastole; shorter the S2-OS interval, more severe the MS
• Mid-diastolic rumbling murmur with presystolic accentuation (if in sinus rhythm); heard best at apex with bell, in left lateral position
• Parasternal heave (RVH)
• Signs of AF, pulmonary hypertension

Investigations

1. ECG - AF; P-mitrale (bifid P wave) in sinus rhythm; RVH
2. CXR - LA enlargement (double cardiac shadow, splaying of carina), pulmonary congestion, Kerley B lines
3. Echo - gold standard; valve area (planimetry), gradient, pulmonary pressure, LA size, LV function

Management

• Medical: Rate control in AF (Digoxin, Beta-blocker); anticoagulation for AF (Warfarin INR 2-3); diuretics; SBE prophylaxis
• Interventional: Balloon Mitral Valvotomy (BMV/PBMV) - percutaneous; Inoue balloon; preferred for pliable non-calcified valve; valve area doubled
• Surgical commissurotomy (open or closed) - for suitable anatomy
• Mitral valve replacement (MVR) - for severe calcification, MR combined, failed BMV
• Indications for intervention: Symptomatic moderate/severe MS (area <1.5 cm²)

---

SUMMARY TABLE: 20-MARK & 15-MARK QUESTION FREQUENCY

---

• Highest priority (must prepare thoroughly): Chronic Bronchitis, Infective Endocarditis, Myocardial Infarction, Bronchiectasis, Carcinoma Lung - these are asked virtually every year
• High priority: ASD, ARDS, Asthma, Angina, Aortic Stenosis, Pleural Effusion, TOF, Hypertension, Rheumatic Fever
• Every answer must follow the format: Definition → Etiology → Pathogenesis → Clinical Features → Investigations → Management → Complications

• No. 16 = Tetralogy of Fallot (already covered as Q12 above - but let me re-check)

• #16 = Pneumothorax (already answered as Q16)
• #18 = Pulmonary TB
• #20 = ARDS (already answered as Q5)

• #14 = Congenital Heart Disease / Pulmonary Stenosis
• #15 = Pulmonary Function Test / Preoperative Assessment for Thoracotomy

---

ANSWERS

---

PART 2, Q16 - PULMONARY TUBERCULOSIS (TB)

Definition

Epidemiology

• India accounts for ~26% of global TB burden
• Airborne transmission (droplet nuclei, 1-5 microns)
• Leading infectious disease cause of death worldwide

Etiology

• Causative organism: Mycobacterium tuberculosis - aerobic, slow-growing, acid-fast bacillus (AFB); Ziehl-Neelsen (ZN) stain - stains red against blue background
• Source: Open (sputum-positive) case; sneezing, coughing, talking
• Risk factors: HIV (most important), malnutrition, diabetes, immunosuppression, alcoholism, poverty, overcrowding, silicosis, end-stage renal disease

Classification

• First infection in a non-sensitized host
• Ghon focus (subpleural lesion, usually right lower lobe)
• Ghon focus + hilar lymphadenopathy = Primary complex (Ranke complex)
• Usually self-limiting; bacilli remain dormant (latent TB)

• Reactivation of dormant bacilli (when immunity falls)
• Typically involves apex of upper lobe (high O2 tension favors growth)
• More severe, progressive disease
• Cavitation common

• Hematogenous dissemination
• Tiny millet-seed sized lesions throughout both lungs
• Life-threatening; associated with HIV, severely immunocompromised

Pathogenesis

1. Inhalation of droplet nuclei containing MTB
2. Bacilli reach alveoli → phagocytosed by alveolar macrophages
3. Macrophages cannot kill MTB → mycobacteria multiply within macrophages
4. Cell-mediated immunity (CMI) develops after 2-8 weeks
5. Granuloma formation: activated macrophages (epithelioid cells), Langhans giant cells, lymphocytes, central caseation (cheesy necrosis) → tubercle
6. Tuberculin sensitivity develops (positive Mantoux)
7. In most: granuloma heals → fibrosis and calcification (Ghon focus)
8. In some: disease progresses → cavitation, spread

Clinical Features

• Fever - low-grade, evening rise, sweating
• Night sweats
• Weight loss, anorexia, malaise
• Fatigue

• Cough - chronic, persistent (>3 weeks) - cardinal symptom
• Mucopurulent or blood-stained sputum
• Hemoptysis - from mild to massive (Rasmussen aneurysm - erosion of pulmonary artery in cavity wall)
• Breathlessness
• Pleuritic chest pain
• Hoarse voice (laryngeal involvement)

• Dullness on percussion (consolidation, fibrosis, effusion)
• Bronchial breathing, crepitations (cavities)
• Amphoric breathing (over large cavity)
• Signs of pleural effusion (common complication)
• Signs of consolidation over upper lobes

Investigations

1. Sputum AFB smear (ZN stain) - 3 samples (spot-early morning-spot); positive if ≥10,000 bacilli/mL; quick but low sensitivity
2. Sputum culture - gold standard; Lowenstein-Jensen (LJ) medium; takes 4-8 weeks; allows sensitivity testing
3. CBNAAT/GeneXpert MTB/RIF - rapid molecular test (2 hours); detects MTB + rifampicin resistance simultaneously; now recommended as first-line diagnostic in India
4. Line probe assay (LPA) - detects first-line and second-line drug resistance
5. Liquid culture (MGIT) - faster than LJ (2 weeks)

1. Chest X-ray - apical shadows, cavitation (thick-walled), fibrosis, pleural effusion, calcification, miliary nodules
2. HRCT chest - more sensitive; tree-in-bud pattern (endobronchial spread), cavities, lymphadenopathy

1. Mantoux test (TST) - Intradermal 5TU PPD on forearm; read at 48-72 hrs; induration >10 mm = positive; >5 mm in HIV; indicates infection (not active disease); can be negative in severe disease/HIV
2. Interferon-gamma release assays (IGRA) - QuantiFERON-TB Gold; more specific than Mantoux; not affected by BCG vaccination

• CBC - anemia, raised ESR
• LFT - before starting DOTS (hepatotoxicity monitoring)
• HIV testing - mandatory
• Sputum induced if patient cannot produce spontaneously
• Bronchoscopy + BAL - if smear-negative and high suspicion

Management - DOTS (Directly Observed Treatment Short-course)

• Intensive phase (2 months): HRZE - Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) daily
• Continuation phase (4 months): HR - Isoniazid + Rifampicin daily
• Total: 6 months (2HRZE + 4HR)

• First test for drug resistance (GeneXpert)
• If sensitive: 2HRZES + 1HRZE + 5HRE (8 months)
• If MDR: second-line drugs

• MDR-TB (Multi-drug resistant): resistant to H + R; treat with second-line drugs (Fluoroquinolones + injectable aminoglycosides) for 18-24 months; shorter regimen (BPaL - Bedaquiline + Pretomanid + Linezolid) now available
• XDR-TB (Extensively drug resistant): resistant to H + R + fluoroquinolone + injectable

• Indicated in: TB meningitis, pericarditis, pleural effusion (large), adrenal TB
• Prednisolone 1-2 mg/kg/day tapered over 6-8 weeks

• Lobectomy/pneumonectomy - for destroyed lung, localized MDR-TB unresponsive to drugs, massive hemoptysis (Rasmussen aneurysm)
• Emergency arterial embolization for massive hemoptysis

Complications

1. Pleural effusion (most common)
2. Massive hemoptysis
3. Pneumothorax (rupture of cavity)
4. Empyema thoracis
5. Bronchiectasis (post-TB)
6. Cor pulmonale (extensive fibrosis)
7. Laryngeal TB
8. MDR/XDR TB
9. Miliary TB / TB meningitis (dissemination)
10. Pericardial TB

Physiotherapy Role

• Pre and post-surgical breathing exercises
• Postural drainage for secretion clearance
• Chest physiotherapy (percussion, vibration)
• Progressive ambulation and exercise
• Respiratory muscle training
• Education on medication adherence, infection control (masks, sunlight exposure of sputum)
• Rehabilitation of residual disability

---

PART 2, Q18 - PULMONARY FUNCTION TESTS (PFT) / PREOPERATIVE ASSESSMENT

---

PART 2, Q20 - ARDS

---

PART 3, Q14 - CONGENITAL HEART DISEASE / PULMONARY STENOSIS

---

CONGENITAL HEART DISEASE - OVERVIEW

Definition

Incidence

• 8 per 1000 live births
• Leading cause of death from birth defects in the first year of life

Classification

1. Ventricular Septal Defect (VSD) - most common CHD (30%)
2. Atrial Septal Defect (ASD)
3. Patent Ductus Arteriosus (PDA)
4. Atrioventricular Septal Defect (AVSD)

1. Pulmonary Stenosis (PS)
2. Aortic Stenosis (congenital)
3. Coarctation of Aorta

1. Tetralogy of Fallot (TOF) - most common cyanotic CHD
2. Transposition of Great Arteries (TGA) - most common cyanotic CHD in neonates
3. Tricuspid Atresia
4. Total Anomalous Pulmonary Venous Return (TAPVR)
5. Truncus Arteriosus
6. Ebstein's Anomaly
7. Pulmonary Atresia

Etiology of CHD

• Chromosomal abnormalities: Down syndrome (Trisomy 21) → AVSD/VSD/ASD; Turner syndrome (45X) → Coarctation; Noonan syndrome → PS
• Single gene mutations

• Rubella infection (PDA, PS, ASD)
• Maternal diabetes (TGA, VSD, hypertrophic CM)
• Alcohol (VSD, ASD, TOF)
• Thalidomide, phenytoin, lithium (Ebstein's anomaly)
• Maternal SLE (congenital heart block)

---

PULMONARY STENOSIS - DETAILED ANSWER

Definition

Types / Classification

1. Valvular PS (most common, ~90%) - leaflet fusion; dome-shaped; poststenotic pulmonary artery dilatation; associated with Noonan syndrome
2. Subvalvular (Infundibular) PS - fibromuscular obstruction below the valve; as seen in Tetralogy of Fallot
3. Supravalvular PS - narrowing above valve; associated with Williams syndrome, Rubella
4. Peripheral PS - narrowing of pulmonary artery branches

Pathophysiology

• Obstruction to RV outflow → RV systolic pressure rises
• RV concentric hypertrophy (compensatory)
• If severe: RV failure → raised RA pressure → right-to-left shunt through PFO/ASD → cyanosis
• Mild PS: well tolerated for decades
• Severe PS (RV-PA gradient >80 mmHg): symptomatic, risk of sudden death

Clinical Features

• Mild PS: asymptomatic (often discovered incidentally)
• Moderate-Severe: dyspnea on exertion, easy fatiguability
• Exercise syncope (severe PS)
• Symptoms of right heart failure (ascites, edema, raised JVP - late)
• Cyanosis only if right-to-left shunting (severe PS with patent foramen ovale)

• Ejection systolic murmur - loudest at left upper sternal border (2nd left intercostal space, pulmonary area); radiates to left shoulder
• Ejection click (in valvular PS) - just before murmur; disappears on inspiration
• Wide split S2 with soft/absent P2 (as pulmonary valve closes late)
• Right ventricular heave (parasternal)
• JVP - prominent 'a' wave (forceful RA contraction against non-compliant RV)
• In Noonan syndrome: short stature, webbed neck, ptosis, hypertelorism
• No clubbing or cyanosis in isolated mild-moderate PS

Investigations

1. ECG - right axis deviation; right ventricular hypertrophy (tall R in V1, deep S in V5/V6); right atrial enlargement (tall peaked P waves)
2. Chest X-ray - post-stenotic dilatation of pulmonary artery; reduced vascular markings (oligemia); right ventricular enlargement
3. Echocardiography (Doppler) - gold standard; measures peak gradient across pulmonary valve; estimates valve area; visualizes RV function; detects associated defects
   • Mild PS: gradient < 36 mmHg
   • Moderate PS: 36-64 mmHg
   • Severe PS: >64 mmHg
4. Cardiac catheterization - measures pressure gradient directly; pre-interventional
5. MRI - RV volume and function assessment

Management

• Mild PS: observation; no intervention needed; regular follow-up echo every 3-5 years
• SBE prophylaxis (if valve malformed - before dental procedures)
• Treat RV failure: diuretics, digoxin
• Prostaglandin E1 (PGE1) - in neonates with severe duct-dependent PS (to maintain PDA until intervention)

• Percutaneous catheter-based procedure
• Balloon inflated across the stenotic pulmonary valve
• Splits the fused commissures
• Immediate and long-term results excellent
• Indications: symptomatic PS OR peak gradient >40-50 mmHg even if asymptomatic
• Success rate: >85%
• Complications: pulmonary regurgitation (mild, usually well tolerated), arrhythmia

• Pulmonary valvotomy (open) - if anatomy unsuitable for BPV (thick, dysplastic valve as in Noonan syndrome)
• Infundibular resection - for subvalvular PS
• Patch enlargement of RVOT
• Pulmonary valve replacement (if severe PR after valvotomy)
• Done via median sternotomy + cardiopulmonary bypass

• Deep breathing exercises, incentive spirometry
• Early mobilization
• Cardiac rehabilitation program
• Regular follow-up for residual PS or PR

Prognosis

• Mild PS: excellent; normal life expectancy
• Moderate/severe corrected early: good long-term outcome
• Uncorrected severe PS: RV failure, sudden cardiac death

---

PART 3, Q15 - PULMONARY FUNCTION TESTS (PFT) AND PREOPERATIVE ASSESSMENT FOR THORACOTOMY

---

PULMONARY FUNCTION TESTS (PFT)

Definition

Types of PFT

• Graphical representation of flow vs volume
• Obstructive pattern: scooped-out expiratory curve
• Restrictive pattern: narrow loop, normal shape

• Measures ability of alveolar membrane to transfer CO from alveolar air to blood
• Normal: 20-30 mL/min/mmHg
• Reduced in: emphysema, IPF, pulmonary hypertension, anemia
• Increased in: polycythemia, pulmonary hemorrhage

• Simple bedside test
• Used for asthma monitoring
• Diurnal variation >20% = asthma

• PaO2 (normal 80-100 mmHg)
• PaCO2 (normal 35-45 mmHg)
• pH (normal 7.35-7.45)
• HCO3- (normal 22-26 mEq/L)
• SaO2 (normal >95%)

Interpretation Patterns

• Administer Salbutamol 400 mcg (4 puffs) via MDI + spacer
• Repeat spirometry after 15-20 minutes
• Positive if FEV1 increases by ≥12% AND ≥200 mL = reversible obstruction (asthma)

• GOLD I: ≥80% (mild)
• GOLD II: 50-79% (moderate)
• GOLD III: 30-49% (severe)
• GOLD IV: <30% (very severe)

Six-Minute Walk Test (6MWT)

• Functional test; measures walking distance in 6 minutes
• Normal: 400-700 m
• Used for: COPD, heart failure, pulmonary hypertension, pre/post-surgical assessment
• SpO2 monitored during test (desaturation indicates exercise-induced hypoxemia)

---

PREOPERATIVE ASSESSMENT FOR THORACOTOMY

Definition

Goals

• Identify patients at high risk for post-operative pulmonary complications (PPCs)
• Optimize lung function before surgery
• Predict post-operative lung function
• Plan physiotherapy intervention

Components of Preoperative Assessment

• Dyspnea grading (MRC scale)
• Exercise tolerance (can patient climb 1-2 flights of stairs = acceptable risk)
• Smoking history (pack years) and cessation status
• Co-morbidities: COPD, asthma, heart disease, diabetes
• Current medications (bronchodilators, anticoagulants)
• Nutritional status

• FEV1 - most important predictor of post-operative risk
  • FEV1 >2 L (or >80% predicted): pneumonectomy safe
  • FEV1 >1.5 L: lobectomy safe
  • FEV1 <0.8 L: very high risk; reconsider surgery
• FVC and FEV1/FVC ratio - obstruction pattern
• DLCO (Diffusing capacity) - reduced DLCO predicts poor outcome even if FEV1 normal

• Formula: ppoFEV1 = preoperative FEV1 × (1 - fraction of functioning segments removed)
• Pneumonectomy removes 45% of segments
• Safe if ppoFEV1 >40% predicted
• High risk if ppoFEV1 < 30%

• PaO2 < 60 mmHg or PaCO2 > 45 mmHg = increased risk
• Indicates need for careful monitoring and post-operative ventilatory support

• Most comprehensive test
• VO2 max (maximum oxygen uptake):

  • 20 mL/kg/min: low risk (suitable for pneumonectomy)

  • 10-20 mL/kg/min: moderate risk
  • <10 mL/kg/min: very high risk; surgery may be contraindicated
• Shuttle walk test / Stair climbing (>5 floors without symptoms = acceptable)

• Assesses regional distribution of ventilation and perfusion
• Used to calculate ppoFEV1 more accurately when considering pneumonectomy
• Identifies which segments contribute most to function

• ECG, echocardiography
• Identify coexisting cardiac disease (IHD, heart failure, arrhythmias)
• Cardiology consultation if needed

• Malnutrition worsens outcomes
• BMI, serum albumin
• Pre-operative nutritional supplementation if needed

Risk Factors for Post-Operative Pulmonary Complications (PPCs)

• FEV1 < 60% predicted
• DLCO < 60% predicted
• Active smoking (within 8 weeks of surgery)
• Age > 70 years
• Obesity
• Poor exercise tolerance
• Presence of COPD, asthma
• Prolonged surgery (>3 hrs)
• Type of resection: pneumonectomy > lobectomy > segmentectomy > wedge

Pre-Operative Physiotherapy Interventions

1. Smoking cessation - minimum 8 weeks before surgery (optimally longer); halves respiratory complications
2. Bronchodilator therapy - optimize airway obstruction with nebulized bronchodilators
3. Airway clearance - postural drainage, ACBT, PEP for patients with sputum (COPD, bronchiectasis)
4. Breathing exercises - diaphragmatic breathing, deep breathing training, incentive spirometry
5. Inspiratory muscle training (IMT) - threshold loading devices to strengthen inspiratory muscles; shown to reduce PPCs
6. General exercise training - aerobic exercise (walking, cycling) to improve VO2 max and exercise tolerance; "prehabilitation"
7. Education:
   • Deep breathing exercises technique
   • Huffing and coughing technique (wound support with pillow after surgery)
   • Early ambulation
   • Incentive spirometry use
   • Importance of smoking cessation

Post-Operative Complications (Related to Thoracotomy)

1. Pulmonary atelectasis - most common PPC; mucus plug, shallow breathing
2. Pneumonia - retained secretions, aspiration
3. Prolonged air leak - bronchopleural fistula
4. Respiratory failure - requiring ventilatory support
5. Cardiac arrhythmias - AF (especially post-pneumonectomy)
6. Hemorrhage, pleural effusion
7. DVT / Pulmonary embolism
8. Post-thoracotomy pain syndrome - neuropathic pain from intercostal nerve damage

Post-Operative Physiotherapy

• Day 0-1: Positioning (head elevated 30°), gentle breathing exercises, early ambulation
• Day 1-2: Active cycle of breathing (ACBT), incentive spirometry, supported coughing
• Day 2-3: Sitting out of bed, short walks
• Weeks 1-4: Progressive walking, arm exercises, stair climbing
• Ongoing: Pulmonary rehabilitation, return to daily activities

---

SUMMARY OF ANSWERS PROVIDED

Note: Part 2 #20 (ARDS) was already fully answered in the previous response as Q5. If you want it re-printed, let me know and I will write it out again separately.

---

VENTRICULAR SEPTAL DEFECT (VSD)

---

Definition

---

Anatomy of Interventricular Septum

1. Perimembranous (membranous) - most common site of VSD (70%)
2. Muscular - completely surrounded by muscle; may be multiple ("Swiss cheese")
3. Inlet (AV canal type) - beneath AV valves; associated with Down syndrome
4. Outlet (supracristal/doubly committed) - beneath pulmonary valve; common in Asians

---

Classification by Size

---

Pathophysiology

1. LV pressure > RV pressure normally
2. Blood flows left-to-right through VSD (acyanotic defect)
3. Increased pulmonary blood flow → pulmonary congestion
4. RV volume and pressure overload → RV enlargement
5. Increased return to LA and LV → LV volume overload
6. Over years: pulmonary vascular disease (pulmonary hypertension) develops
7. When pulmonary resistance equals systemic resistance: shunt reversal → right-to-left → Eisenmenger syndrome → cyanosis
8. Small VSD: high pressure gradient across defect → loud murmur; RV pressure normal; benign course; may close spontaneously
9. Large VSD: pressures equalize → soft murmur; Eisenmenger risk is high

---

Spontaneous Closure

• Muscular VSDs: close spontaneously in 80% by age 5 years
• Small perimembranous: may close (tricuspid valve tissue occludes defect)
• Large VSDs: rarely close

---

Clinical Features

Symptoms

• Small VSD: Asymptomatic; murmur detected on routine examination
• Large VSD:
  • Breathlessness, poor feeding, failure to thrive (infants)
  • Recurrent chest infections (pneumonia)
  • Excessive sweating during feeds
  • Dyspnea on exertion
  • Fatigue
• Eisenmenger VSD (late):
  • Cyanosis (central)
  • Clubbing
  • Dyspnea, syncope
  • Signs of right heart failure

Signs

• Thrill - palpable at left lower sternal border (harsh murmur)
• Pansystolic (holosystolic) murmur - loudest at left lower sternal border (4th ICS); radiation across precordium; "harsh blowing" quality
• Apical mid-diastolic murmur - if large shunt (increased mitral flow)
• Parasternal heave - RV enlargement
• Displaced, hyperdynamic apex - LV volume overload
• S3 gallop - if heart failure
• Loud P2 - if pulmonary hypertension
• Eisenmenger: cyanosis + clubbing + loud P2 + absent VSD murmur

---

Investigations

1. ECG

• Small VSD: Normal
• Moderate: LV hypertrophy (tall R in V5-V6)
• Large: Biventricular hypertrophy
• Eisenmenger: RV hypertrophy, right axis deviation

2. Chest X-ray

• Small: Normal
• Moderate/Large:
  • Cardiomegaly (LV + RV enlargement)
  • Increased pulmonary vascular markings (pulmonary plethora)
  • Prominent pulmonary artery
• Eisenmenger: Pulmonary artery dilatation; reduced peripheral vascular markings ("pruning")

3. Echocardiography (Gold Standard)

• Visualizes defect location, size, number
• Doppler: measures pressure gradient; estimates RV pressure and pulmonary artery pressure
• Assesses LV and RV function
• Detects associated defects (AR - aortic regurgitation in supracristal VSD)

4. Cardiac Catheterization

• Oxygen step-up in right ventricle (diagnostic of VSD)
• Qp:Qs ratio - pulmonary to systemic flow ratio
  • Qp:Qs >1.5:1 = significant left-to-right shunt
  • Qp:Qs >2:1 = surgical indication
• Pulmonary vascular resistance measurement - critical for surgical decision

5. MRI

• For complex anatomy or when echo inadequate

---

Management

Medical Management

• Diuretics (Furosemide) - reduce pulmonary congestion
• ACE inhibitors (Captopril/Enalapril) - reduce afterload, improve symptoms
• Digoxin - improve contractility, control heart rate
• High-calorie feeds (nasogastric if needed) - combat failure to thrive
• Treatment of infections (chest infections common)
• Oxygen therapy

• Small VSDs: observe; follow up echocardiography every 6-12 months
• Regular monitoring for AR (especially outlet VSD), endocarditis

---

Interventional/Surgical Management

Indications for Closure

• Qp:Qs > 1.5:1 to 2:1
• Symptoms of heart failure not controlled medically
• Failure to thrive
• Recurrent chest infections
• LV volume overload
• Development of aortic regurgitation (supracristal VSD)
• Before Eisenmenger syndrome develops (pulmonary vascular resistance still reversible)
• Contraindication: established Eisenmenger syndrome (fixed pulmonary hypertension)

---

1. Device Closure (Catheter-Based) - Less Invasive

• Amplatzer Muscular VSD Occluder or Amplatzer Membranous VSD Occluder
• Suitable for: muscular VSDs, selected perimembranous VSDs
• Done in cardiac catheterization lab under fluoroscopy + echo guidance
• Device deployed on both sides of septum (double-disc)
• Advantages: no sternotomy, shorter hospital stay
• Complications: complete heart block (perimembranous), residual shunt, device embolization

---

2. Open Heart Surgical Repair - Standard Treatment

• Direct suture closure - for small VSDs
• Patch closure - for large VSDs; using Dacron (synthetic) or pericardial patch
• Access through right atrium (transatrial approach) - avoids right ventriculotomy
• Right ventriculotomy - only if necessary (for outlet/muscular VSDs)

• Perimembranous VSD: bundle of His runs along posteroinferior rim → risk of complete heart block (AV block) - suture carefully away from conduction system
• Multiple muscular VSDs: may need pulmonary artery banding first (stage 1), then complete repair later

• ICU monitoring
• Chest physiotherapy
• Early mobilization
• Echocardiography to confirm closure

---

Conditions Requiring Open Heart Surgery

1. VSD (large, symptomatic)
2. ASD (ostium primum)
3. Tetralogy of Fallot
4. Transposition of Great Arteries
5. Total Anomalous Pulmonary Venous Return (TAPVR)
6. Valve surgeries (Aortic/Mitral)
7. CABG
8. Ventricular aneurysm repair

---

Complications of Untreated Large VSD

1. Eisenmenger syndrome - irreversible pulmonary hypertension + cyanosis
2. Infective endocarditis - SBE
3. Aortic regurgitation - especially supracristal VSD (aortic cusp prolapse into defect)
4. Heart failure
5. Pulmonary hypertension
6. Recurrent respiratory infections
7. Growth retardation

---

Physiotherapy Role

• Pre-operative:
  • Breathing exercises (diaphragmatic, deep breathing)
  • Education to parents and patient
  • Airway clearance if respiratory infection present
• Post-operative:
  • Deep breathing and incentive spirometry (from day 1)
  • Supported coughing (pillow splinting)
  • Progressive ambulation (sitting → standing → walking)
  • Chest physiotherapy for secretion clearance
  • Limb exercises to prevent DVT
  • Cardiac rehabilitation and graded exercise program
  • Monitor SpO2 and HR during activity

---

---

PNEUMONIA

---

Definition

---

Classification

By Setting of Acquisition

By Radiological Pattern

1. Lobar (Consolidative) Pneumonia - entire lobe affected; Streptococcus pneumoniae
2. Bronchopneumonia (Lobular) - patchy consolidation; Staphylococcus, Gram-negative organisms
3. Interstitial Pneumonia - affects alveolar walls; atypical organisms (Mycoplasma, viruses)

---

Etiology / Causative Organisms

Community-Acquired Pneumonia (CAP)

Hospital-Acquired Pneumonia (HAP/VAP)

• Gram-negative bacilli: Pseudomonas aeruginosa, Klebsiella, E. coli, Acinetobacter
• Staphylococcus aureus (including MRSA)
• More resistant organisms, higher mortality

Aspiration Pneumonia

• Mixed anaerobes (from oropharynx): Bacteroides, Fusobacterium, Peptostreptococcus
• Right lower lobe (most common site - gravity + right bronchus is more vertical)
• Risk: altered consciousness, dysphagia, neuromuscular disease

---

Risk Factors

• Extremes of age (very young, elderly)
• Smoking
• Alcohol
• Immunosuppression (HIV, steroids, chemotherapy)
• Chronic lung disease (COPD, bronchiectasis)
• Diabetes mellitus
• Malnutrition
• Aspiration risk: stroke, bulbar palsy, general anesthesia
• Hospitalization, mechanical ventilation

---

Pathogenesis

1. Microorganisms enter lower respiratory tract (inhalation, aspiration, hematogenous spread)
2. Overcome host defenses (mucociliary clearance, alveolar macrophages, cough reflex)
3. Bacterial multiplication in alveoli → inflammatory response
4. Alveolar exudate: polymorphs, bacteria, fibrin, red cells
5. Lung consolidation → impaired gas exchange → hypoxemia

Stages of Lobar Pneumonia (Laennec)

1. Congestion (0-24 hrs): Vascular engorgement, serous exudate; lung heavy and red
2. Red Hepatization (2-4 days): Alveoli filled with RBCs, fibrin, neutrophils; lung solid like liver (red)
3. Grey Hepatization (4-8 days): RBCs lysed; fibrin + neutrophils; lung grey
4. Resolution (8+ days): Macrophages clear debris; lung returns to normal

---

Clinical Features

Symptoms

• Fever - sudden onset, high grade, rigors, chills
• Productive cough - mucopurulent, rusty sputum (S. pneumoniae), blood-stained
• Pleuritic chest pain - sharp, worse on breathing/coughing
• Dyspnea - breathlessness, increased respiratory rate
• Hemoptysis
• Constitutional: malaise, headache, myalgia, anorexia

• Gradual onset, dry cough, prominent constitutional symptoms
• Extrapulmonary: rash (erythema multiforme in Mycoplasma), diarrhea (Legionella), ear pain, meningism

Signs

• Fever, tachycardia, tachypnea
• Decreased chest expansion on affected side
• Dullness on percussion (consolidation)
• Bronchial breathing (hollow, tubular sounds) - consolidation conducts sound better
• Increased vocal resonance / vocal fremitus (whispering pectoriloquy)
• Crepitations (fine, inspiratory) - over consolidated area
• Central cyanosis in severe pneumonia
• Signs of pleural effusion (parapneumonic) - stony dull + absent breath sounds

Severity Assessment - CURB-65 Score

• Score 0-1: Outpatient treatment
• Score 2: Consider hospital admission
• Score 3-5: Severe pneumonia; ICU consideration

---

Investigations

Radiological

1. Chest X-ray - most important; consolidation (opacification), lobar/segmental distribution; silhouette sign; air bronchogram; pleural effusion
2. CT chest - more sensitive; if CXR inconclusive; detects complications (abscess, empyema)

Microbiological

1. Sputum Gram stain and culture - before antibiotics; identifies organism; sensitivity testing
2. Blood cultures (2 sets) - positive in ~20% of bacteremic pneumonia; important for severe CAP
3. Urinary antigen tests:
   • Streptococcus pneumoniae urinary antigen - rapid (2 hrs); specific; not affected by prior antibiotics
   • Legionella urinary antigen - for serogroup 1 (most common)
4. Nasopharyngeal swab / PCR - for atypical organisms (Mycoplasma, Chlamydia, viruses)
5. Bronchoscopy + BAL - for immunocompromised, non-responding, ventilated patients; protected specimen brush

Biochemical / Haematological

1. CBC - leukocytosis (WBC >11,000) with neutrophilia; leukopenia in severe pneumonia (poor prognosis)
2. CRP, ESR, Procalcitonin - raised; procalcitonin helps guide antibiotic duration
3. Renal function, electrolytes, LFT - CURB-65; hyponatremia in Legionella
4. ABG - if SpO2 < 94% or severe pneumonia; assess hypoxemia and need for ventilation
5. Cold agglutinins - raised in Mycoplasma pneumonia (positive in 50-75%)
6. Serology - for atypical organisms (4-fold rise in paired sera)

---

Management

General Measures

• Oxygen therapy - maintain SpO2 ≥94% (88-92% in COPD)
• Adequate hydration (IV fluids if unable to drink)
• Analgesia - for pleuritic pain (NSAID or paracetamol); adequate pain relief helps breathing and coughing
• Antipyretics
• Nutritional support
• DVT prophylaxis (LMWH) in hospitalized patients

---

Antibiotic Treatment

Community-Acquired Pneumonia (CAP)

• Amoxicillin 500 mg TDS orally × 5 days (covers S. pneumoniae)
• If atypical suspected: Doxycycline 200 mg stat then 100 mg OD or Clarithromycin 500 mg BD

• Amoxicillin + Clarithromycin (covers both typical and atypical)
• Or: Co-amoxiclav + Clarithromycin
• Duration: 5-7 days

• IV Co-amoxiclav (or Cefuroxime/Ceftriaxone) + IV Clarithromycin
• If Pseudomonas risk: Piperacillin-tazobactam or Ciprofloxacin
• Duration: 7-10 days

Hospital-Acquired Pneumonia (HAP)

• Piperacillin-tazobactam (covers Pseudomonas) + consider MRSA cover (Vancomycin/Teicoplanin)
• Or: Meropenem for highly resistant organisms
• Duration: 7 days (if responds); 14-21 days if Pseudomonas or necrotizing pneumonia

Aspiration Pneumonia

• Co-amoxiclav (anaerobic + aerobic cover)
• Or: Clindamycin + Cephalosporin
• Add Metronidazole for enhanced anaerobic cover

Atypical Pneumonia

• Macrolide (Clarithromycin, Azithromycin)
• Or Doxycycline
• Legionella: Levofloxacin (drug of choice) or Azithromycin

---

Supportive / Ventilatory Support (Severe Pneumonia)

• HFNO (High-Flow Nasal Oxygen) - for persistent hypoxemia despite conventional O2
• NIV (BiPAP/CPAP) - for hypercapnic respiratory failure
• Mechanical ventilation - if NIV fails; ICU
• Prone positioning (if ARDS develops)

---

Specific Complications Management

---

Physiotherapy Management (Very Important for BPT)

Goals

• Improve airway clearance
• Prevent and treat atelectasis
• Improve oxygenation
• Assist in weaning from ventilator
• Restore exercise capacity

Techniques

• Sitting upright (45°) or high side-lying - improves ventilation
• Avoid lying on affected side for prolonged time (promotes secretion pooling)
• Head-down position (modified postural drainage) for secretion drainage

• ACBT (Active Cycle of Breathing Technique): Breathing control → thoracic expansion exercises → forced expiration technique (FET/huffing) → repeat
• Postural drainage - position patient so gravity drains affected segment
• Percussion and vibration - manual chest physiotherapy (MCP) over affected area
• PEP mask / Flutter / Acapella - oscillating PEP to loosen secretions

• Diaphragmatic breathing - reduce work of breathing
• Deep breathing / thoracic expansion exercises
• Incentive spirometry - sustain maximal inspiration; expand atelectatic areas

• For patients unable to cough effectively
• Endotracheal/oropharyngeal suctioning in ICU patients

• Supported/splinted coughing (patient holds pillow against chest)
• Manually assisted cough (in paralyzed/weak patients)

• Early mobilization - even ICU patients
• Sitting out of bed → standing → walking (step-up)
• Improves secretion clearance, prevents DVT, improves oxygenation

• Patient positioning (30° head-up or prone)
• Manual hyperinflation (MHI) - "bagging" to mobilize secretions in ventilated patients
• Weaning protocol support

• Progressive walking program
• Return to activities of daily living
• Respiratory muscle training

---

Complications of Pneumonia

1. Parapneumonic effusion (most common complication)
2. Empyema (infected pleural effusion)
3. Lung abscess - cavitation; seen in Staph, Klebsiella, anaerobes
4. Septicemia / Bacteremia - especially S. pneumoniae
5. Septic shock - life-threatening
6. Respiratory failure → ARDS
7. Meningitis (hematogenous spread)
8. Pericarditis
9. Hepatitis, glomerulonephritis (immune-mediated)
10. Delayed resolution → organizing pneumonia

---

Prevention

• Pneumococcal vaccine: PCV13 (conjugate) + PPSV23 (polysaccharide); recommended for >65 years, immunocompromised, chronic diseases
• Influenza vaccine: Annual; prevents influenza and secondary bacterial pneumonia
• Smoking cessation
• Hand hygiene and infection control (HAP prevention)
• Aspiration precautions (head-up position, oral hygiene in ventilated patients)
• Early mobilization of hospitalized patients

---

Prognosis

• Mild CAP: full recovery expected in 2-4 weeks
• Severe CAP: mortality 10-30%
• HAP/VAP: mortality 20-50%
• Radiological clearing may take 4-6 weeks (especially elderly/COPD)
• If CXR not clear at 6 weeks: repeat + investigate for underlying malignancy